Skip to main content
. 2016 Dec 18;123:34–41. doi: 10.1016/j.rmed.2016.12.010

Table 2.

Characteristics of patients at presentation with exacerbation with rhinovirus or other viruses at exacerbation.

Rhinovirus
(n = 34)
Other viruses
(n = 10)
p-value
Gender (% females) 68 70 0.89
Age 29 (9) 41 (17) 0.06
Smokers (% never; former; current) 65; 15; 20 60; 30; 10 0.47
Packyears (among former and current smokers) 6.0 (5.4) 1.7 (1.6) 0.15
Atopic (%) 62 40 0.22
ICS dose (daily budesonide eq.) 200 (0–2400) 800 (0–800) 0.34



ACQ 3.4 (1.4) 2.3 (1.4) 0.03
FEV1%pred. 77.2 (16.0) 90.8 (15.5) 0.02
FVC %pred. 87.1 (14.4) 94.9 (11.8) 0.13
Beta-2-agonist within 8 h? (%) 46 25 0.29



FeNO (ppb)a 29 (23–37) 24 (15–38) 0.41
Blood eosinophils (× 109 cells/L) 0.07 (0–1.32) 0.13 (0–0.41) 0.84
Blood neutrophils (× 109 cells/L) 6.2 (2.1–14.1) 3.6 (2.9–10.2) 0.13
Total IgE (× 103 IU/L)a 167 (85–328) 96 (31–298) 0.41
CRP (mg/L)a
8.5 (6.0–12.0)
8.2 (3.5–19.1)
0.93

n = 27
n = 9

Sputum total cell count (× 106/ml)a 1.0 (0.6–1.7) 2.2 (0.9–5.4) 0.11
Sputum eosinophils (× 106/ml)a 0.07 (0.04–0.13) 0.06 (0.02–0.16) 0.80
Sputum %-eosinophilsa 1.2 (0.5–3.0) 0.9 (0.3–3.2) 0.75
Sputum neutrophils (× 106/ml)a 0.5 (0.2–0.9) 1.1 (0.3–3.8) 0.20
Sputum %-neutrophilsa 45.9 (32.0–66.0) 51.3 (28.3–93.0) 0.75
a

Log-transformed and presented as geometric mean (95% CI).